Seven Fleet Capital Management LP Buys 66,158 Shares of Dianthus Therapeutics, Inc. $DNTH

Seven Fleet Capital Management LP lifted its stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 451.6% during the first quarter, Holdings Channel reports. The fund owned 80,809 shares of the company’s stock after buying an additional 66,158 shares during the quarter. Dianthus Therapeutics comprises 2.1% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 13th largest position. Seven Fleet Capital Management LP’s holdings in Dianthus Therapeutics were worth $6,781,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. First Horizon Corp acquired a new stake in Dianthus Therapeutics in the first quarter worth $32,000. Caitong International Asset Management Co. Ltd bought a new stake in Dianthus Therapeutics in the fourth quarter valued at $40,000. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter valued at about $27,000. Russell Investments Group Ltd. acquired a new position in shares of Dianthus Therapeutics during the third quarter valued at about $64,000. Finally, ABS Direct Equity Fund LLC bought a new position in shares of Dianthus Therapeutics during the 1st quarter worth about $179,000. 47.53% of the stock is owned by institutional investors.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares of the company’s stock, valued at approximately $362,480. This trade represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Ryan Savitz sold 31,249 shares of Dianthus Therapeutics stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $101.03, for a total value of $3,157,086.47. Following the sale, the executive vice president owned 31,249 shares in the company, valued at $3,157,086.47. This trade represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 87,779 shares of company stock worth $7,985,235 in the last 90 days. Insiders own 3.02% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Wall Street Zen upgraded Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wedbush increased their price target on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Wolfe Research reissued an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $117.82.

Dianthus Therapeutics Price Performance

DNTH opened at $106.92 on Friday. Dianthus Therapeutics, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $114.55. The firm has a market capitalization of $5.85 billion, a P/E ratio of -25.89 and a beta of 1.20. The company’s 50-day moving average is $92.63 and its 200 day moving average is $78.34.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative net margin of 12,998.50% and a negative return on equity of 27.30%. On average, equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.82 earnings per share for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.